INVOKANA™ Provides Greater Improvements in Blood Glucose than Sitagliptin in Adults with Diabetes

The FINANCIAL — 300 milligrams (mg) of INVOKANATM (canagliflozin) provided greater improvements in blood glucose control compared to a commonly prescribed therapy, sitagliptin, in adult patients with type 2 diabetes taking background metformin, according to a new 52-week Phase 3 clinical study conducted by Janssen Research & Development, LLC (Janssen).

100 mg of INVOKANA™ provided similar improvements in blood glucose control to sitagliptin, and both doses of INVOKANA™ resulted in greater secondary endpoint reductions in body weight and blood pressure, the study showed.

Results of a second Phase 3 study, also in adult patients taking metformin, showed greater improvements in blood glucose control with 300 mg INVOKANA™ and similar improvements with 100 mg INVOKANA™ compared to another commonly prescribed therapy, glimepiride, over a period of 104 weeks. Both doses of INVOKANA™ provided greater secondary endpoint reductions in body weight and blood pressure than glimepiride.

Both studies showed INVOKANA™ was generally well tolerated, with similar rates of discontinuation due to adverse events in the INVOKANA™ and comparator treatment groups. The results of the two trials were presented today and are among a total of 17 presentations on INVOKANA™ at the American Diabetes Association (ADA) 73rd Annual Scientific Sessions.

“Although a variety of type 2 diabetes medications have long been available, blood glucose levels remain above recognized goals for many patients, increasing their risks for complications associated with this devastating disease,” said Fernando Lavalle Gonzalez, M.D., from the Endocrinology Department, University Hospital at Universidad Autónoma de Nuevo León in Mexico, lead investigator on the sitagliptin comparison study. “These results suggest INVOKANA™ is a viable treatment option when metformin alone or other therapies do not provide adequate glycemic control,” he added.

The INVOKANA™ recommended starting dose is 100 mg once daily. In patients tolerating the starting dose, who have an eGFR of 60 mL/min/1.73 m2 or greater, and require additional glycemic control, the dose can be increased to 300 mg once daily.